Caeregen Therapeutics gets $1.4m Phase 2 SBIR grant from NIH/NEI
The grant is intended to support the further development of CTR-107 (Noregen), a novel regenerative therapeutic designed to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Jul 23
The grant is intended to support the further development of CTR-107 (Noregen), a novel regenerative therapeutic designed to…
17 Jul 23
GHz-Class NMR, Structural Biology assisted by Artificial Intelligence, a New Scientific Software Division and Innovative Helium Solutions at…
17 Jul 23
Deenova, the undisputed leading supplier of innovative pharmacy automation solutions for healthcare facilities, is delighted to announce the…
17 Jul 23
Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for…
17 Jul 23
Olympus Corporation, a global medical technology company, announced publication of study data demonstrating that the minimally invasive iTind™…
17 Jul 23
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases.
17 Jul 23
Combined company is expected to have cash balance of approximately $170m at close, which is expected to provide…
17 Jul 23
The Company intends to use the funds awarded by the National Institutes of Health for completion of its…
17 Jul 23
Colchicine's Approval Heightens the Need for Technologies Detecting Inflammation Specifically Related to Coronary Arteries
17 Jul 23
Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates